Shares in Swedish engineering group Sandvik fell sharply after its second-quarter order intake failed to meet analyst expectations, raising concerns about future demand despite record revenue and profit.
Shares of the Swiss staffing firm surged after BNP Paribas raised its rating, citing an improving cyclical outlook for the industry and potential for stronger earnings momentum.
BlossomHill Therapeutics has filed for an initial public offering on the Nasdaq Global Select Market under the ticker symbol BLSM. The company has not yet disclosed the number of shares or the price range for the offering.
Shares of the Finnish pharmaceutical firm surged after it reported second-quarter results that beat market expectations, driven by its prostate cancer drug Nubeqa, and raised its full-year financial guidance.
Financial disclosures reveal U.S. Small Business Administration head Kelly Loeffler made two separate investments in SpaceX and its predecessor xAI, which saw their value multiply after the company's record-breaking initial public offering.
The German pharmaceutical company's stock declined after the financial watchdog BaFin disclosed an investigation into potential irregularities in its 2025 financial statements, focusing on a €63.2 million receivable.
Shares of the automotive safety supplier slid after a significant restructuring charge related to its European operations weighed on its second-quarter financial results, compounding pressure from a management change and broader market weakness.
French software company Dassault is negotiating a potential $2 billion acquisition of drug trial software maker ArisGlobal from Nordic Capital, according to a Financial Times report, in a move to deepen its presence in the life sciences sector.
The investment bank raised its rating on European stocks, citing an improving cyclical outlook and fading uncertainties, while also increasing its price target for the EuroStoxx 50 index.
